Last reviewed · How we verify

NCT05290272

Validity of AI in Treatment of the Musculoskeletal Conditions by Vifive

Completed NA Last updated 22 November 2024
What this trial tests

NA trial testing ViFIVE Digital Care Progrma in Shoulder Adhesive Capsulitis in 35 participants. Completed in 6 June 2024.

Timeline
30 January 2023
Primary endpoint
6 June 2024
6 June 2024

Quick facts

Lead sponsorStanford University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment35
Start date30 January 2023
Primary completion6 June 2024
Estimated completion6 June 2024
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Stanford University

Who can join

Adults 18 to 70, any sex, with Shoulder Adhesive Capsulitis or Knee Osteoarthritis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the efficacy of the 12-week ViFive program, a vision-based artificial intelligent digital care plan for chronic knee pain. ViFive digital care plan is delivered by a physical therapy team consisting of physical therapists and a personal coach. We aim to understand the safety and efficacy of this vision artificial intelligent based home exercise program.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Digital therapeutics in the clinic.
    Phan P, Mitragotri S, Zhao Z. · · 2023 · cited 39× · PMID 37476062 · DOI 10.1002/btm2.10536

Verify or expand the search:

Other recruiting trials for Shoulder Adhesive Capsulitis

Currently open trials in the same condition.

Other Stanford University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05290272.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing